Emerging therapeutic targets for osteoporosis

References

• Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367:2010–2081.
   PubMed Web of Science ®Google Scholar
• Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009;301:513–521.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Cooper C, Rizzoli R, et al. European Society for Clinical and Economic aspects of Osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int. 2017;28(7):2023–2034.
   PubMed Web of Science ®Google Scholar
• Seeman E, Delmas PD. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354:2250–2261.
   PubMed Web of Science ®Google Scholar
• Martin TJ, Seeman E. Bone remodeling: its local regulation and the emergence of bone fragility. Best Pract Res Clin Endo Endocrinol Metab. 2008;22:701–722.
   PubMed Web of Science ®Google Scholar
• Bellido T. Osteocyte-driven bone remodeling. Calcif Tissue Int. 2014;94:25–34.
   PubMed Web of Science ®Google Scholar
• Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts and prospects. J Clin Invest. 2005;115:3318–3325.
   PubMed Web of Science ®Google Scholar
• Gennari L, Rotatori S, Bianciardi S, et al. Treatment needs and current options for postmenopausal osteoporosis. Expert Opin Pharmacother. 2016;17:1141–1152.
   PubMed Web of Science ®Google Scholar
• Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017;5:898–907.
   PubMed Web of Science ®Google Scholar
• Merlotti D, Falchetti A, Chiodini I, et al. Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis. Expert Opin Pharmacother. 2019;20:805–811.
   PubMed Web of Science ®Google Scholar
• Russell G. Bisphosphonates from bench to bedside. Ann NY Acad Sci. 2006;1068:367–401.
   PubMed Web of Science ®Google Scholar
• Maraka S, Kennel KA. Bisphosphonates for the prevention and treatment of osteoporosis. BMJ. 2015;351:h3783.
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. HORIZON pivotal fracture trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–1822.
   PubMed Web of Science ®Google Scholar
• Reid IR, Horne AM, Mihov B, et al. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med. 2018;379:2407–2416.
   PubMed Web of Science ®Google Scholar
• McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013;126:13–20.
   PubMed Web of Science ®Google Scholar
• Dennison EM, Cooper C, Kanis JA, et al. Fracture risk following intermission of osteoporosis therapy. Osteoporos Int. 2019;30:1733–1743.
   PubMed Web of Science ®Google Scholar
• Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. Trends Endocrinol Metab. 2012;23:576–581.
   PubMed Web of Science ®Google Scholar
• Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the women’s health initiative randomized trial. JAMA. 2003;290:1729–1738.
   PubMed Web of Science ®Google Scholar
• Levin VA, Jiang X, Kagan R. Estrogen therapy for osteoporosis in the modern era. Osteoporos Int. 2018;29:1049–1055.
   PubMed Web of Science ®Google Scholar
• Gennari L, Merlotti D, Valleggi F, et al. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging. 2007;24:361–379.
   PubMed Web of Science ®Google Scholar
• Komm BS, Mirkin S. An overview of current and emerging SERMs. J Steroid Biochem Mol Biol. 2014;143:207–222.
   PubMed Web of Science ®Google Scholar
• Mirkin S, Komm BS. Tissue-selective estrogen complexes for postmenopausal women. Maturitas. 2013;76:213–220.
   PubMed Web of Science ®Google Scholar
• Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008;29:155–192.
   PubMed Web of Science ®Google Scholar
• Nakashima T, Hayashi M, Fukunaga T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17:1231–1234.
   PubMed Web of Science ®Google Scholar
• McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821–831.
   PubMed Web of Science ®Google Scholar
• Lewiecki EM. New and emerging concepts in the use of denosumab for the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2018;10:209–223.
   PubMed Web of Science ®Google Scholar
• Lyu H, Jundi B, Xu C, et al. Comparison of denosumab and bisphosphonates in patients with osteoporosis: a meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2019;104:1753–1765.
   PubMed Web of Science ®Google Scholar
• Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5:513–523.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: a post Hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33:190–198.
   PubMed Web of Science ®Google Scholar
• Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone. 2017;105:11–17.
   PubMed Web of Science ®Google Scholar
• Anastasilakis AD, Papapoulos SE, Polyzos SA, et al. Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial. J Bone Miner Res. 2019;34:2220–2228.
   PubMed Web of Science ®Google Scholar
• Kendler D, Chines A, Clark P, et al. Bone mineral density after transitioning from denosumab to alendronate. J Clin Endocrinol Metab. 2019 Oct 26. pii: dgz095. DOI: 10.1210/clinem/dgz095. [Epub ahead of print] PubMed PMID: 31665314.
   Google Scholar
• Guañabens N, Moro-Álvarez MJ, Casado E, et al. The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment. Endocrine. 2019;64:441–455.
   PubMed Web of Science ®Google Scholar
• Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357:905–916.
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–1441.
   PubMed Web of Science ®Google Scholar
• Graeff C, Chevalier Y, Charlebois M, et al. Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Miner Res. 2009;24:1672–1680.
   PubMed Web of Science ®Google Scholar
• McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005;165:1762–1768.
   PubMed Web of Science ®Google Scholar
• Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391:230–240.
   PubMed Web of Science ®Google Scholar
• Hattersley G, Dean T, Corbin BA, et al. Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology. 2016;57:141–149.
   Google Scholar
• Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis. JAMA. 2016;316:722.
   PubMed Web of Science ®Google Scholar
• Poole KES, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. Faseb J. 2005;19:1842–1844.
   PubMed Web of Science ®Google Scholar
• Wijenayaka AR, Kogawa M, Lim HP, et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011;6:e25900.
   PubMed Web of Science ®Google Scholar
• Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375:1532–1543.
   PubMed Web of Science ®Google Scholar
• Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377:1417–1427.
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, et al. One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res. 2019;34:419–428.
   PubMed Web of Science ®Google Scholar
• Leder BZ, Neer RM, Wyland JJ, et al. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab. 2009;94:2915–2921.
   PubMed Web of Science ®Google Scholar
• Ebina K, Hashimoto J, Kashii M, et al. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. J Bone Miner Metab. 2017;35:91–98.
   PubMed Web of Science ®Google Scholar
• McClung MR, Brown JP, Diez-Perez A, et al. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res. 2018;33:1397–1406.
   PubMed Web of Science ®Google Scholar
• Bone HG, Cosman F, Miller PD, et al. ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab. 2018;103:2949–2957.
   PubMed Web of Science ®Google Scholar
• Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390:1585–1594.
   PubMed Web of Science ®Google Scholar
• Kendler DL, Bone HG, Massari F, et al. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int. 2019;30(12):2437–2448.
   PubMed Web of Science ®Google Scholar
• Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015;386:1147–1155.
   PubMed Web of Science ®Google Scholar
• Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349:1207–1215.
   PubMed Web of Science ®Google Scholar
• Cosman F, Eriksen EF, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH (1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 2011;26:503–511.
   PubMed Web of Science ®Google Scholar
• Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013;382:50–56.
   PubMed Web of Science ®Google Scholar
• Deal C, Omizo M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res. 2005;20:1905–1911.
   PubMed Web of Science ®Google Scholar
• Costa AG, Cusano NE, Silva BC, et al. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol. 2011;7:447–456.
   PubMed Web of Science ®Google Scholar
• Langdahl B, Binkley N, Bone H, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res. 2012;27:2251–2258.
   PubMed Web of Science ®Google Scholar
• Eisman JA, Bone HG, Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three year continued therapy and resolution of effect. J Bone Miner Res. 2011;26:242–251.
   PubMed Web of Science ®Google Scholar
• McClung MR, O’Donoghue ML, Papapoulos SE, et al. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes Endocrinol. 2019;7:899–911.
   PubMed Web of Science ®Google Scholar
• Drake MT, Clarke BL, Oursler MJ, et al. Cathepsin K inhibitors for osteoporosis: biology, potential clinical utility, and lessons learned. Endocr Rev. 2017;38:325–350.
   PubMed Web of Science ®Google Scholar
• Lu J, Wang M, Wang Z, et al. Advances in the discovery of cathepsin K inhibitors on bone resorption. J Enzyme Inhib Med Chem. 2018;33:890–904.
   PubMed Web of Science ®Google Scholar
• Kartner N, Manolson MF. Novel techniques in the development of osteoporosis drug therapy: the osteoclast ruffled-border vacuolar H(+)-ATPase as an emerging target. Expert Opin Drug Discov. 2014;9:505–522.
   PubMed Web of Science ®Google Scholar
• Holliday LS. Vacuolar H(+)-ATPases (V-ATPases) as therapeutic targets: a brief review and recent developments. Biotarget. 2017 Dec;1:18.
   PubMedGoogle Scholar
• Liu X, Qu X, Nie T, et al. The beneficial effects of bisphosphonate-enoxacin on cortical bone mass and strength in ovariectomized rats. Front Pharmacol. 2017;8:355.
   PubMed Web of Science ®Google Scholar
• Soriano P, Montgomery C, Geske R, et al. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell. 1991;64:693–702.
   PubMed Web of Science ®Google Scholar
• Marzia M, Sims NA, Voit S, et al. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol. 2000;151:311–320.
   PubMed Web of Science ®Google Scholar
• de Vries TJ, Mullender MG, van Duin MA, et al. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts. Mol Cancer Res. 2009;7:476–488.
   PubMed Web of Science ®Google Scholar
• Hannon RA, Clack G, Rimmer M, et al. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending dose phase I trial. J Bone Miner Res. 2010;25:463–471.
   PubMed Web of Science ®Google Scholar
• Hannon RA, Finkelman RD, Clack G, et al. Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study. Bone. 2012;50:885–892.
   PubMed Web of Science ®Google Scholar
• Furuya M, Kikuta J, Fujimori S, et al. Direct cell-cell contact between mature osteoblasts and osteoclasts dynamically controls their functions in vivo. Nat Commun. 2018;9:300.
   PubMed Web of Science ®Google Scholar
• Morvan F, Boulukos K, Clément-Lacroix P, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res. 2006;21:934–945.
   PubMed Web of Science ®Google Scholar
• Li J, Sarosi I, Cattley RC, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone. 2006;39:754–766.
   PubMed Web of Science ®Google Scholar
• Li X, Grisanti M, Fan W, et al. Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J Bone Miner Res. 2011;26:2610–2621.
   PubMed Web of Science ®Google Scholar
• Glantschnig H, Scott K, Hampton R, et al. A rate-limiting role for Dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody. J Pharmacol Exp Ther. 2011;338:568–578.
   PubMed Web of Science ®Google Scholar
• Iyer SP, Beck JT, Stewart AK, et al. A phase IB multicentre dose-determination study of BHQ880 incombination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol. 2014;167:366–375.
   PubMed Web of Science ®Google Scholar
• Yao W, Cheng Z, Shahnazari M, et al. Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. J Bone Miner Res. 2010;25:190–199.
   PubMed Web of Science ®Google Scholar
• Cho HY, Choi HJ, Sun HJ, et al. Transgenic mice overexpressing secreted frizzled-related proteins (sFRP)4 under the control of serum amyloid P promoter exhibit low bone mass but did not result in disturbed phosphate homeostasis. Bone. 2010;47:263–271.
   PubMed Web of Science ®Google Scholar
• Florio M, Gunasekaran K, Stolina M, et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun. 2017;7:11505.
   Web of Science ®Google Scholar
• Clement-Lacroix P, Ai M, Morvan F, et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci U S A. 2005;102:17406–17411.
   PubMed Web of Science ®Google Scholar
• Gambardella A, Nagaraju CK, O’Shea PJ, et al. Glycogen synthase kinase-3α/β inhibition promotes in vivo amplification of endogenous mesenchymal progenitors with osteogenic and adipogenic potential and their differentiation to the osteogenic lineage. J Bone Miner Res. 2011;26:811–821.
   PubMed Web of Science ®Google Scholar
• Marsell R, Sisask G, Nilsson Y, et al. GSK-3 inhibition by an orally active small molecule increases bone mass in rats. Bone. 2012;50:619–627.
   PubMed Web of Science ®Google Scholar
• Mercken EM, Mitchell SJ, Martin-Montalvo A, et al. SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass. Aging Cell. 2014;13:787–796.
   PubMed Web of Science ®Google Scholar
• Zainabadi K, Liu CJ, Caldwell ALM, et al. SIRT1 is a positive regulator of in vivo bone mass and a therapeutic target for osteoporosis. PLoS One. 2017;12:e0185236.
   PubMed Web of Science ®Google Scholar
• Iyer S, Han L, Bartell SM, et al. Sirtuin1 (Sirt1) promotes cortical bone formation by preventing β-catenin sequestration by FoxO transcription factors in osteoblast progenitors. J Biol Chem. 2014;289:24069–24078.
   PubMed Web of Science ®Google Scholar
• Wang H, Hu Z, Wu J, et al. Sirt1 promotes osteogenic differentiation and increases alveolar bone mass via Bmi1 activation in mice. J Bone Miner Res. 2019;34:1169–1181.
   PubMed Web of Science ®Google Scholar
• Ornstrup MJ, Harsløf T, Kjær TN, et al. Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial. J Clin Endocrinol Metab. 2014;99:4720–4729.
   PubMed Web of Science ®Google Scholar
• Joshua J, Schwaerzer GK, Kalyanaraman H, et al. Soluble guanylate cyclase as a novel treatment target forosteoporosis. Endocrinology. 2014;155:4720–4730.
   PubMed Web of Science ®Google Scholar
• Napoli N, Chandran M, Pierroz DD, et al. IOF bone and diabetes working group. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2017;13:208–219.
   PubMed Web of Science ®Google Scholar
• Kalyanaraman H, Schwaerzer G, Ramdani G, et al. Protein kinase G activation reverses oxidative stress and restores osteoblast function and bone formation in male mice with Type 1 diabetes. Diabetes. 2018;67:607–623.
   PubMed Web of Science ®Google Scholar
• ia T, Wang YN, Zhang J, et al. Cinaciguat in combination with insulin induces a favorable effect on implant osseointegration in type 2 diabetic rats. Biomed Pharmacother. 2019;118:109216.
   PubMed Web of Science ®Google Scholar
• Kalyanaraman H, Ramdani G, Joshua J, et al. A novel, direct NO donor regulates osteoblast and osteoclast functions and increases bone mass in ovariectomized mice. J Bone Miner Res. 2017;32:46–59.
   PubMed Web of Science ®Google Scholar
• Wu XB, Li Y, Schneider A, et al. Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in noggin-overexpressing mice. J Clin Invest. 2003;112:924–934.
   PubMed Web of Science ®Google Scholar
• Garrett IR, Chen D, Gutierrez G, et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest. 2003;111:1771–1782.
   PubMed Web of Science ®Google Scholar
• Howe JG, Hill RS, Stroncek JD, et al. Treatment of bone loss in proximal femurs of postmenopausal osteoporotic women with AGN1 local osteo-enhancement procedure (LOEP) increases hip bone mineral density and hip strength: a long-term prospective cohort study. Osteoporos Int. 2019 Dec 4 Epub ahead of print. DOI:10.1007/s00198-019-05230-0.
   Google Scholar
• Ikebuchi Y, Aoki S, Honma M, et al. Coupling of bone resorption and formation by RANKL reverse signalling. Nature. 2018;561:195–200.
   PubMed Web of Science ®Google Scholar
• Anastasilakis AD, Polyzos SA, Makras P, et al. Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment. Osteoporos Int. 2013;24(7):2127–2132.
   PubMed Web of Science ®Google Scholar
• Lotinun S, Pearsall RS, Horne WC, et al. Activin receptor signaling: a potential therapeutic target for osteoporosis. Curr Mol Pharmacol. 2012;5:195–204.
   PubMedGoogle Scholar
• Lodberg A, Eijken M, van der Eerden BCJ, et al. A soluble activin type IIA receptor mitigates the loss of femoral neck bone strength and cancellous bone mass in a mouse model of disuse osteopenia. Bone. 2018;110:326–334.
   PubMed Web of Science ®Google Scholar
• Lotinun S, Pearsall RS, Davies MV, et al. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolicantiresorptive effect in Cynomolgus monkeys. Bone. 2010;46:1082–1088.
   PubMed Web of Science ®Google Scholar
• Ruckle J, Jacobs M, Kramer W, et al. Single-dose, randomized, doubleblind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res. 2009;24:744–752.
   PubMed Web of Science ®Google Scholar
• Santini V. Of blood and bone: the sotatercept adventure. Lancet Haematol. 2018;5:e54–e55.
   PubMed Web of Science ®Google Scholar
• Verlinden L, Vanderschueren D, Verstuyf A. Semaphorin signaling in bone. Mol Cell Endocrinol. 2016;432:66–74.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Nakashima T, Taniguchi M, et al. Osteoprotection by semaphorin 3A. Nature. 2012;485:69–74.
   PubMed Web of Science ®Google Scholar
• Yang K, Miron RJ, Bian Z, et al. A bone-targeting drug-delivery system based on Semaphorin 3A gene therapy ameliorates bone loss in osteoporotic ovariectomized mice. Bone. 2018;114:40–49.
   PubMed Web of Science ®Google Scholar
• Negishi-Koga T, Shinohara M, Komatsu N, et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med. 2011;17(11):1473–1480.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wei L, Miron RJ, et al. Anabolic bone formation via a site-specific bone-targeting delivery system by interfering with semaphorin 4D expression. J Bone Miner Res. 2015;30(2):286–296.
   PubMed Web of Science ®Google Scholar
• Gambari L, Lisignoli G, Cattini L, et al. Sodium hydrosulfide inhibits the differentiation of osteoclast progenitor cells via NRF2-dependent mechanism. Pharmacol Res. 2014;87:99–112.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang R, Liu X, et al. Hydrogen sulfide maintains mesenchymal stem cell function and bone homeostasis via regulation of Ca(2+) channel sulfhydration. Cell Stem Cell. 2014;15:66–78.
   PubMed Web of Science ®Google Scholar
• Grassi F, Tyagi AM, Calvert JW, et al. Hydrogen sulfide is a novel regulator of bone formation implicated in the bone loss induced by estrogen deficiency. J Bone Miner Res. 2016;31:949–963.
   PubMed Web of Science ®Google Scholar
• Rapposelli S, Gambari L, Digiacomo M, et al. A Novel H2S-releasing Amino-Bisphosphonate which combines bone anti-catabolic and anabolic functions. Sci Rep. 2017;7:11940.
   PubMed Web of Science ®Google Scholar
• Vidal C, Li W, Santner-Nanan B, et al. The kynurenine pathway of tryptophan degradation is activated during osteoblastogenesis. Stem Cells. 2015;33:111–121.
   PubMed Web of Science ®Google Scholar
• Refaey ME, McGee-Lawrence ME, Fulzele S, et al. Kynurenine, a tryptophan metabolite that accumulates with age, induces bone loss. J Bone Miner Res. 2017;32:2182–2193.
   PubMed Web of Science ®Google Scholar
• Kim BJ, Hamrick MW, Yoo HJ, et al. The detrimental effects of kynurenine, a tryptophan metabolite, on human bone metabolism. J Clin Endocrinol Metab. 2019;104:2334–2342.
   PubMed Web of Science ®Google Scholar
• Bozec A, Zaiss MM, Kagwiria R, et al. T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway. Sci Transl Med. 2014;6:235ra60.
   PubMed Web of Science ®Google Scholar
• Meshcheryakova A, Mechtcheriakova D, Pietschmann P. Sphingosine 1-phosphate signaling in bone remodeling: multifaceted roles and therapeutic potential. Expert Opin Ther Targets. 2017;21:725–737.
   PubMed Web of Science ®Google Scholar
• Park YE, Musson DS, Naot D, et al. Cell-cell communication in bone development and whole-body homeostasis and pharmacological avenues for bone disorders. Curr Opin Pharmacol. 2017;34:21–35.
   PubMed Web of Science ®Google Scholar
• Han HQ, Zhou X, Mitch WE, et al. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol. 2013;45:2333–2347.
   PubMed Web of Science ®Google Scholar
• Lodberg A, van der Eerden BCJ, Boers-Sijmons B, et al. A follistatin-based molecule increases muscle and bone mass without affecting the red blood cell count in mice. Faseb J. 2019;33:6001–6010.
   PubMed Web of Science ®Google Scholar
• Rooks D, Praestgaard J, Hariry S, et al. Treatment of sarcopenia with bimagrumab: results from a phase ii, randomized, controlled, proof-of-concept study. J Am Geriatr Soc. 2017;65(9):1988–1995.
   PubMed Web of Science ®Google Scholar
• Rooks DS, Laurent D, Praestgaard J, et al. Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy. J Cachexia Sarcopenia Muscle. 2017;8(5):727–734.
   PubMed Web of Science ®Google Scholar
• Kaji H. Effects of myokines on bone. Bonekey Rep. 2016;5:826.
   PubMedGoogle Scholar
• Cornish J, Wang T, Lin JM. Role of marrow adipocytes in regulation of energy metabolism and bone homeostasis. Curr Osteoporos Rep. 2018;16(2):116–122.
   PubMed Web of Science ®Google Scholar
• Lombardi G, Sanchis-Gomar F, Perego S, et al. Implications of exercise-induced adipo-myokines in bone metabolism. Endocrine. 2016;54(2):284–305.
   PubMed Web of Science ®Google Scholar
• Rendina-Ruedy E, Rosen CJ. Bone-fat interaction. Endocrinol Metab Clin North Am. 2017;46:41–50.
   PubMed Web of Science ®Google Scholar
• van Zoelen EJ, Duarte I, Hendriks JM, et al. TGFbeta-induced switch from adipogenic to osteogenic differentiation of human mesenchymal stem cells: identification of drug targets for prevention of fat cell differentiation. Stem Cell Res Ther. 2016;7:123.
   PubMed Web of Science ®Google Scholar
• Marciano DP, Kuruvilla DS, Boregowda SV, et al. Pharmacological repression of PPARγ promotes osteogenesis. Nat Commun. 2015;6:7443.
   PubMed Web of Science ®Google Scholar
• Fairfield H, Rosen CJ, Reagan MR. Connecting bone and fat: the potential role for sclerostin. Curr Mol Biol Rep. 2017;3:114–121.
   PubMedGoogle Scholar
• Ramasamy SK, Kusumbe AP, Wang L, et al. Endothelial Notch activity promotes angiogenesis and osteogenesis in bone. Nature. 2014;507:376–380.
   PubMed Web of Science ®Google Scholar
• Kusumbe AP, Ramasamy SK, Adams RK. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature. 2014;507:323–328.
   PubMed Web of Science ®Google Scholar
• Xu R, Yallowitz A, Qin A, et al. Targeting skeletal endothelium to ameliorate bone loss. Nat Med. 2018;24:823–833.
   PubMed Web of Science ®Google Scholar
• Yang YS, Xie J, Wang D, et al. Bone-targeting AAV-mediated silencing of Schnurri-3 prevents bone loss in osteoporosis. Nat Commun. 2019;10:2958.
   PubMed Web of Science ®Google Scholar
• Fasano A, Not T, Wang W, et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet. 2000;355:1518e9.
   Web of Science ®Google Scholar
• Mokkala K, Röytiö H, Munukka E, et al. Gut microbiota richness and composition and dietary intake of overweight pregnant women are related to serum zonulin concentration, a marker for intestinal permeability. J Nutr. 2016;146:1694–1700.
   PubMed Web of Science ®Google Scholar
• Sommer F, Bäckhed F. The gut microbiota–masters of host development and physiology. Nat Rev Microbiol. 2013;11:227–238.
   PubMed Web of Science ®Google Scholar
• Surana NK, Kasper DL. Deciphering the tete-a-tete between the microbiota and the immune system. J Clin Invest. 2014;124:4197–4203.
   PubMed Web of Science ®Google Scholar
• McCabe L, Britton RA, Parameswaran N. Prebiotic and probiotic regulation of bone health: role of the intestine and its microbiome. Curr Osteoporos Rep. 2015;13:363–371.
   PubMed Web of Science ®Google Scholar
• Hernandez CJ, Guss JD, Luna M, et al. Links between the microbiome and bone. J Bone Miner Res. 2016;31:1638–1646.
   PubMed Web of Science ®Google Scholar
• McCabe LR, Irwin R, Schaefer L, et al. Probiotic use decreases intestinal inflammation and increases bone density in healthy male but not female mice. J Cell Physiol. 2013;228:1793–1798.
   PubMed Web of Science ®Google Scholar
• Ohlsson C, Engdahl C, Fåk F, et al. Probiotics protect mice from ovariectomy-induced cortical bone loss. PLoS One. 2014;9:e92368.
   PubMed Web of Science ®Google Scholar
• Britton RA, Irwin R, Quach D, et al. Probiotic L. reuteri treatment prevents bone loss in a menopausal ovariectomized mouse model. J Cell Physiol. 2014;229:1822–1830.
   PubMed Web of Science ®Google Scholar
• Sjögren K, Engdahl C, Henning P, et al. The gut microbiota regulates bone mass in mice. J Bone Miner Res. 2012;27:1357–1367.
   PubMed Web of Science ®Google Scholar
• Chen KL, Madak-Erdogan Z. Estrogen and microbiota crosstalk: should we pay attention? Trends Endocrinol Metab. 2016;27:752–755.
   PubMed Web of Science ®Google Scholar
• Li JY, Chassaing B, Tyagi AM, et al. Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics. J Clin Invest. 2016;126:2049–2063.
   PubMed Web of Science ®Google Scholar
• Nilsson AG, Sundh D, Bäckhed F, et al. Lactobacillus reuteri reduces bone loss in older women with low bone mineral density: a randomized, placebo-controlled, double-blind, clinical trial. J Intern Med. 2018;284:307–317.
   PubMed Web of Science ®Google Scholar
• Schiellerup SP, Skov-Jeppesen K, Windeløv JA, et al. Gut hormones and their effect on bone metabolism. potential drug therapies in future osteoporosis treatment. Front Endocrinol (Lausanne). 2019;26(10):75.
   Google Scholar
• Ding KH, Shi XM, Zhong Q, et al. Impact of glucose-dependent insulinotropic peptide on age-induced bone loss. J Bone Miner Res. 2008;23:536–543.
   PubMed Web of Science ®Google Scholar
• Henriksen DB, Alexandersen P, Hartmann B, et al. Four-month treatment with GLP-2 significantly increases hip BMD. A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone. 2009;45:833–842.
   PubMed Web of Science ®Google Scholar
• Mardini HE, de Villiers WJ. Teduglutide in intestinal adaptation and repair: light at the end of the tunnel. Expert Opin Investig Drugs. 2008;17:945–951.
   PubMed Web of Science ®Google Scholar
• Ceccarelli E, Guarino EG, Merlotti D, et al. Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism. Front Endocrinol (Lausanne). 2013;4:73.
   PubMedGoogle Scholar
• Mabilleau G, Gobron B, Bouvard B, et al. Incretin-based therapy for the treatment of bone fragility in diabetes mellitus. Peptides. 2018;100:108–113.
   PubMed Web of Science ®Google Scholar
• Spohn SN, Mawe GM. Non-conventional features of peripheral serotonin signalling - the gut and beyond. Nat Rev Gastroenterol Hepatol. 2017;14:412–420.
   PubMed Web of Science ®Google Scholar
• Amso Z, Kowalczyk R, Watson M, et al. Structure activity relationship study on the peptide hormone preptin, a novel bone-anabolic agent for the treatment of osteoporosis. Org Biomol Chem. 2016;14:9225–9238.
   PubMed Web of Science ®Google Scholar
• Kawai M, Kinoshita S, Yamazaki M, et al. Intestinal clock system regulates skeletal homeostasis. JCI Insight. 2019;4:121798.
   PubMed Web of Science ®Google Scholar
• Manolagas SC. The quest for osteoporosis mechanisms and rational therapies: how far we’ve come, how much further we need to go. J Bone Miner Res. 2018;33:371–385.
   PubMed Web of Science ®Google Scholar
• López-Otín C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell. 2013;153:1194–1217.
   PubMed Web of Science ®Google Scholar
• Manolagas SC, Parfitt AM. What old means to bone. Trends Endocrinol Metab. 2010;21:369–374.
   PubMed Web of Science ®Google Scholar
• Almeida M, O’Brien CA. Basic biology of skeletal aging: role of stress response pathways. J Gerontol A Biol Sci Med Sci. 2013;68:1197–1208.
   PubMed Web of Science ®Google Scholar
• Farr J, Khosla S. Cellular senescence in bone. Bone. 2019;121:121–133.
   PubMed Web of Science ®Google Scholar
• Almeida M, Han L, Martin-Millan M, et al. Skeletal involution by age associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem. 2007;282:27285–27297.
   PubMed Web of Science ®Google Scholar
• Garrett IR, Boyce BF, Oreffo RO, et al. Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest. 1990;85:632–639.
   PubMed Web of Science ®Google Scholar
• Almeida M, Porter RM. Sirtuins and FoxOs in osteoporosis and osteoarthritis. Bone. 2019;121:284–292.
   PubMed Web of Science ®Google Scholar
• Ambrogini E, Que X, Wang S, et al. Oxidation-specific epitopes restrain bone formation. Nat Commun. 2018;9:2193.
   PubMed Web of Science ®Google Scholar
• Farr JN, Fraser DG, Wang H, et al. Identification of senescent cells in the bone microenvironment. J Bone Miner Res. 2016;31:1920–1929.
   PubMed Web of Science ®Google Scholar
• Piemontese M, Almeida M, Robling AG, et al. Old age causes de novo intracortical bone remodeling and porosity in mice. JCI Insight. 2017;2:e93771.
   PubMed Web of Science ®Google Scholar
• Farr JN, Xu M, Weivoda MM, et al. Targeting cellular senescence prevents age-related bone loss in mice. Nat Med. 2017;23:1072–1079.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wu J, Zhu Y, et al. Therapeutic application of mesenchymal stem cells in bone and joint diseases. Clin Exp Med. 2014;14:13–24.
   PubMed Web of Science ®Google Scholar
• Gennari L, Rotatori S, Bianciardi S, et al. Appropriate models for novel osteoporosis drug discovery and future perspectives. Expert Opin Drug Discov. 2015;10:1201–1216.
   PubMed Web of Science ®Google Scholar
• Marie PJ. Targeting integrins to promote bone formation and repair. Nat Rev Endocrinol. 2013;9:288–295.
   PubMed Web of Science ®Google Scholar
• Gennari L, Bianciardi S, Merlotti D. MicroRNAs in bone diseases. Osteoporos Int. 2017;28:1191–1213.
   PubMed Web of Science ®Google Scholar